Glenmark Pharma needs many things to fall in place to stand tall
Investors will keep a close eye on the execution of the company’s plans.
For Glenmark Pharmaceuticals Ltd stock, CY22 has been rather dull. The company’s shares, which fell to a 52-week low in June, have gained nearly 26% since then. However, for 2022 as a whole, they are still down 17% so far.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more